Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo discontinues pactimibe

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Japanese firm is discontinuing its atherosclerosis agent pactimibe following the ACAT inhibitor's failure to show a significant effect in a 534-patient coronary intravascular ultrasound study. The primary endpoint was change from baseline in percent atheroma volume at 18 months. Secondary measures "showed a lower effect of pactimibe on atherosclerosis than standard of care alone and no beneficial effect on the frequency of cardiovascular events," Daiichi says Oct. 26. "As a result, all ongoing clinical studies with pactimibe will be discontinued." The company plans to present an expanded analysis at the American Heart Association's Scientific Sessions Nov. 15...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS003101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel